Refine your search�ソスF     
Report No.
 - 

PET studies of neuroendcrine tumors by using $$^{76}$$Br-$$m$$-bromobenzylguanidine ($$^{76}$$Br-MBBG)

Watanabe, Shigeki; Hanaoka, Hirofumi*; Liang, J. X.*; Iida, Yasuhiko*; Watanabe, Satoshi; Endo, Keigo*; Ishioka, Noriko

$$^{131}$$I-$$m$$-Iodobenzylgunanidine ($$^{131}$$I-MIBG), functional analogue of norepinephrine, has been employed for the therapy of neuroendcrine tumors which express norepinephrine transporter (NET). $$^{123}$$I-MIBG scintigraphy has been also used for diagnosis of NET positive tumors such as detecting metastasis, investigating suitability and monitoring response to the treatment with $$^{131}$$I-MIBG. However, $$^{123}$$I-MIBG scintigraphy has limitation to diagnose small legions due to its lower sensitivity and spatial resolution. Since positron emission tomography (PET) is superior to scintigraphy, positron emitter labeled MIBG has potential to improve diagnostic ability of NET positive neuroendcrine tumors. Then, we have reveal the utility of positron emitter $$^{76}$$Br labeled m-bromobenzylguanidine ($$^{76}$$Br-MBBG) as a PET tracer for NET positive tumor.

Accesses

:

- Accesses

InCites™

:

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.